MetaCap

Immix Biopharma (IMMX) vs Olema Oncology (OLMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immix Biopharma (IMMX) has outperformed Olema Oncology (OLMA) over the past year, gaining 60.7% versus a loss of 69.7%. Olema Oncology is the larger company by market cap ($615.0 million vs $583.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMMX+60.74%OLMA-69.70%
+250%+81%-88%
Nov 21, 20251 yearNov 20, 2026
IMMX+74.00%OLMA-27.03%
+265%+85%-94%
Dec 13, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMMX versus OLMA key metrics
MetricIMMXOLMA
Share price$6.96$7.02
Market cap$583.33M$615.00M
1-day change-1.14%-1.82%
YTD return+33.08%-71.92%
1-year return+60.74%-69.70%
5-year return—-66.36%
EPS (TTM)$-0.83$-2.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-29.40M$-162.45M
52-week high$15.10$36.26
52-week low$3.78$6.24
Distance from 52-week high-53.91%-80.64%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+243.82%+405.70%
Average volume1.45M1.27M
Shares outstanding83.81M87.61M
Employees21131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMX has outperformed OLMA by 130.4 percentage points over the past year.

About Immix Biopharma

IMMX stock →

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Olema Oncology

OLMA stock →

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

IMMX vs OLMA FAQ

Which is bigger, Immix Biopharma or Olema Oncology?

Olema Oncology (OLMA) is larger, with a market capitalization of $615.00M compared with $583.33M for Immix Biopharma (IMMX).

Which stock has performed better over the past year, IMMX or OLMA?

IMMX returned +60.74% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.

Are Immix Biopharma and Olema Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons